SK Bioscience has signed a contract to produce vaccine candidate materials for MSD 'Ebola'
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
Paul Lee
hoondork1977@alphabiz.co.kr | 2023-05-09 06:11:12
[Alpha Biz=(Chicago) Reporter Paul Lee] SK Bioscience consigns next-generation Zaire Ebola vaccine candidate material (CMO) of global healthcare company MSD.
SK Bioscience announced on August 8 that it has signed a new production contract with MSD for the next-generation Zaire Ebola vaccine candidate material.
The MSD is developing a candidate for the next-generation Zaire Ebola vaccine that has improved the process efficiency and thermal stability of the Zaire Ebola vaccine ERVEBO, which is currently in use with the Hilleman Research Institute (Hilleman Laboratories), an international nonprofit research institute. In the future, if the candidate material is successfully developed and approved by regulators, it is expected to contribute to the global supply and accessibility of the Zaire Ebola virus vaccine. The candidate material will be transferred by SK Bioscience and produced at Andong L-House and supplied to international organizations after obtaining approval from related health authorities.
In particular, SK Bioscience plans to expand its consignment development production (CDMO) business with CMO, starting with this contract.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 2Korean Air and LCC Affiliates Enter Emergency Management as Fuel Costs Surge Amid Middle East Conflict
- 3Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure
- 4Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 5Daesang Executive Arrested in KRW 10 Trillion Sweetener Price-Fixing Probe; CEOs Avoid Detention
- 6China Vanke Posts Record Loss as Property Slump Deepens Financial Strain